Cookies on GOV.UK

We use some essential cookies to make this website work.

We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.

We also use cookies set by other sites to help us deliver content from their services.

You have accepted additional cookies. You can change your cookie settings at any time.

You have rejected additional cookies. You can change your cookie settings at any time.

View cookies

Benefits
Births, death, marriages and care
Business and self-employed
Childcare and parenting
Citizenship and living in the UK
Crime, justice and the law
Disabled people
Driving and transport
Education and learning
Employing people
Environment and countryside
Housing and local services
Money and tax
Passports, travel and living abroad
Visas and immigration
Working, jobs and pensions

Government activity

Departments
Departments, agencies and public bodies
News
News stories, speeches, letters and notices
Guidance and regulation
Detailed guidance, regulations and rules
Research and statistics
Reports, analysis and official statistics
Policy papers and consultations
Consultations and strategy
Transparency
Data, Freedom of Information releases and corporate reports

Search

Search GOV.UK

Home
Health and social care
Medicines, medical devices
Vigilance, safety alerts and guidance
Alerts and recalls

Drug Safety Update

From:: Medicines and Healthcare products Regulatory Agency

Alerts, recalls and safety information: drugs and medical devices
Drug Safety Update: monthly PDF newsletter

Search Drug Safety Update

Skip to results

Filter

58 updates

Therapeutic area

Anaesthesia and intensive care

Breastfeeding

Cancer

Cardiovascular disease and lipidology

Dentistry

Dermatology

Dispensing GP practices

Ear, nose and throat

Endocrinology, diabetology and metabolism

GI, hepatology and pancreatic disorders

Haematology

Immunology and vaccination

Immunosuppression and transplantation

Infectious disease

Neurology

Nutrition and dietetics

Obstetrics, gynaecology and fertility

Ophthalmology

Paediatrics and neonatology

Pain management and palliation

Pregnancy

Psychiatry

Radiology and imaging

Respiratory disease and allergy

Rheumatology

Urology and nephrology

Published

Published after

For example, 2005 or 21/11/2014

Published before

For example, 2005 or 21/11/2014

58 updates

About Immunosuppression and transplantation

Go to search results

58 updates

Skip to results

Get emails
Subscribe to feed

58 updates

About Immunosuppression and transplantation

Oral tacrolimus products: prescribe and dispense by brand name only, to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection

The growing number of oral tacrolimus products available on the market increases the potential for inadvertent switching between products, which has been associated with reports of toxicity and graft rejection. Therefore, to…
- Therapeutic area: Immunosuppression and transplantation
- Published: 11 December 2014
Fingolimod (Gilenya▼): not recommended for patients at known risk of cardiovascular adverse events

New advice for extended early monitoring for those with significant bradycardia or heart block after first dose.
- Therapeutic area: Immunosuppression and transplantation
- Published: 11 December 2014
Sirolimus: different immunoassays for therapeutic drug monitoring—risk of incorrect dose adjustment

Needs a summary
- Therapeutic area: Immunosuppression and transplantation
- Published: 11 December 2014
Drug alert: recall of Gaviscon Advance Peppermint Flavour, Boots Heartburn Relief Peppermint Flavour, Peptac Peppermint Liquid, and Peptac Liquid Aniseed Flavour

Batches of this medicine are being recalled from the market because of low levels of microbial contamination.
- Therapeutic area: Cancer and 2 others
- Published: 11 December 2014
Mycophenolate mofetil: pure red cell aplasia

Healthcare professionals should consider a dose reduction or discontinuation of mycophenolate mofetil if patients develop pure red cell aplasia.
- Therapeutic area: Immunosuppression and transplantation
- Published: 11 December 2014
Info on progressive multifocal leukoencephalopathy (PML) from Yellow Card reports

Spontaneous reporting on the Yellow Card portal has provided important information in the identification of PML associated with some drugs.
- Therapeutic area: Cancer and 3 others
- Published: 11 December 2014
Ecoflac infusion solutions: risk of air embolism

To avoid the risk of air embolism, these products should not be infused under pressure.
- Therapeutic area: Anaesthesia and intensive care and 22 others
- Published: 11 December 2014
Corticosteroids: early psychiatric side-effects

Risk of early psychiatric side-effects is one of several important safety issues for healthcare professionals to discuss with patients and carers, who should seek urgent medical advice in the event of any worrying symptoms.
- Therapeutic area: Anaesthesia and intensive care and 9 others
- Published: 11 December 2014

Previous page : 1 of 2

Get emails
Subscribe to feed

Is this page useful?

Thank you for your feedback

Help us improve GOV.UK

Don’t include personal or financial information like your National Insurance number or credit card details.

This field is for robots only. Please leave blank

What were you doing?

What went wrong?

Help us improve GOV.UK

To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).

Services and information

Benefits
Births, death, marriages and care
Business and self-employed
Childcare and parenting
Citizenship and living in the UK
Crime, justice and the law
Disabled people
Driving and transport
Education and learning
Employing people
Environment and countryside
Housing and local services
Money and tax
Passports, travel and living abroad
Visas and immigration
Working, jobs and pensions

Government activity

Departments
News
Guidance and regulation
Research and statistics
Policy papers and consultations
Transparency
How government works
Get involved

All content is available under the Open Government Licence v3.0, except where otherwise stated